Publications by authors named "H Monaghan"
Article Synopsis
- The TESTING trial found that corticosteroids reduce kidney failure risk in patients with IgA nephropathy (IgAN), but they also increase serious side effects, highlighting the need for better biomarkers.
- This study focuses on urinary soluble CD163 (u-sCD163), suggesting it correlates with treatment response and kidney health in IgAN patients receiving steroid therapy.
- The results indicate that higher u-sCD163 levels are linked to better steroid responses and that corticosteroids significantly lower u-sCD163 levels, which may reduce the risk of kidney progression.
Introduction: The therapeutic effects of steroids in immunoglobulin A nephropathy (IgAN) global (TESTING) study reported that methylprednisolone reduces the risk of major kidney events in individuals with IgAN at high risk of disease progression compared to supportive care alone but is associated with increased serious adverse events (SAEs) primarily with full-dose therapy. The risk benefit balance of the reduced-dose methylprednisolone regimen is examined in this prespecified analysis of the reduced-dose cohort of the TESTING trial.
Methods: Between 2017 and 2019, patients with IgAN, proteinuria ≥1 g/d despite 3 months of renin-angiotensin-system blockade and estimated glomerular filtration rate (eGFR) 30 to 120 ml/min per 1.
Article Synopsis
- The study aimed to determine the effectiveness of methylprednisolone, a glucocorticoid, in preventing kidney function decline in patients with IgA nephropathy who are at high risk for such decline.
- Conducted as a double-blind, randomized clinical trial with 503 participants across multiple countries, the results indicated that those receiving methylprednisolone had a significantly lower rate of serious kidney outcomes compared to those on placebo.
- After 4.2 years of follow-up, the primary composite outcome occurred in 28.8% of the methylprednisolone group versus 43.1% of the placebo group, showcasing methylprednisolone's potential benefits for patients with this kidney condition.
Background: Multiple observational studies have associated metformin prescription with reduced progression of abdominal aortic aneurysm (AAA). The Metformin Aneurysm Trial (MAT) will test whether metformin reduces the risk of AAA rupture-related mortality or requirement for AAA surgery (AAA events) in people with asymptomatic aneurysms.
Methods: MAT is an international, multi-centre, prospective, parallel-group, randomised, placebo-controlled trial.
Introduction: Despite optimal current care, up to 30% of individuals suffering from immunoglobulin A nephropathy (IgAN) will develop kidney failure requiring dialysis or kidney transplantation. The Therapeutic Evaluation of STeroids in IgA Nephropathy Global (TESTING) study was designed to assess the benefits and risks of steroids in people with IgAN. We report the trial design as well as the baseline characteristics of study participants.
View Article and Find Full Text PDF